The Heidelberg Health Economics Summer School 2025 - offered by the the Institute for Innovation & Valuation in Health Care (InnoVal^HC) under the auspices of the Ruprecht-Karls-University Heidelberg - has been an unsurpassed opportunity to learn more about the state-of-the-art of cost-effectiveness analysis (CEA) as a tool to inform health technology assessments (HTAs).
Again, this year´s Summer School "Basic Program" took place at the NOBIS event center in Bruneck, South Tyrol / Italy.

For more detailed information regarding the Health Economics Summer School programs, please visit the Institute´s website.

Michael Schlander was invited as a speaker to the PPIC | Pharma Pricing & Access Innovation Conference in Basel / Switzerland from June 03-05, and he presented under the heading ´Early Strategic Decision Making in Drug Development: The Role of Health Economics for Market Access´ - exploring the strategic importance and benefits of early advise consultations for pharmaceutical manufacturers. His focus was on the national HTA agencies G-BA (Germany), HAS (France) and NICE (England and Wales) with examples of global trends. Topics included the choice of surrogate endpoints and targeted subpopulations for HTAs, and the optimal use of patient reported outcomes (PROs) data in the context of international HTA trends, including the relevance of socioeconomic burden.

Michael Schlander attended the ISPOR 2025 Conference in Montreal, QC / Canada from May 13-16, and he had scientific contributions on ´The Socioeconomic Impact of Cancer and Cancer Care on Patients and Their Relatives: Assessing the Content Validity of Dedicated Patient-Reported Outcomes Measurement (PROM) Instruments´ and ´More than “Financial Toxicity”: The Socioeconomic Impact of Cancer and Cancer Care on Patients and Their Relatives´.